Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$7.67MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Najat Khan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 600
- Beta
- 1.07
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 0.83
Financials
Revenue
$7.67M+789.8%Net Income
$-131.00MEBITDA
$-112.53MFree Cash Flow
$-107.91MEPS (diluted)
$-0.25Shares Outstanding (diluted)
532.46M+216.3%Operating Expenses
$131.15MCash & Debt
$545.68MRevenue by Segment (annual)
$74.68MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $74.68M | $-644.76M | $-1.44 |
| 2024 | $58.84M | $-463.66M | $-1.69 |
| 2023 | $43.88M | $-328.07M | $-1.58 |
| 2022 | $39.68M | $-239.48M | $-1.36 |
| 2021 | $10.00M | $-186.48M | $-1.05 |
| 2020 | $3.41M | $-87.01M | $-0.52 |
| 2019 | $1.71M | $-62.52M | $-0.37 |
Valuation
RXRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+37.93%Social Signal Score
Mentions (10)
- Newszacks.com·7d ago·Neutral
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.7, indicating a -1.2% shift from the previous trading day.
View source ↗ - Newszacks.com·11d ago·Negative
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.
View source ↗ - Newsbusinesswire.com·15d ago·Negative
…odel CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion's RNA Foundation Model. Tempus and Recursion have extended their multi-year data partnership through November 2029. The companies share a mission to use foundation models to advance precision medicine, and entered into …
View source ↗ - Newszacks.com·19d ago·Neutral
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·25d ago·Neutral
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.
View source ↗ - Newszacks.com·31d ago·Neutral
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·32d ago·Positive
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
View source ↗ - Newsseekingalpha.com·56d ago·Negative
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments, but further commercial validation is pending. The internal pipeline, led by REC-4881 for FAP, potentially lags competitors (more data is required) and is unlikely to generat
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.24 per share
Typical surprise -4.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.25 vs $-0.24miss
- Wed, May 6$-0.22 vs $-0.30beat
- Wed, Feb 25$-0.21 vs $-0.28beat
- Wed, Nov 5$-0.36 vs $-0.38beat
- Tue, Aug 5$-0.41 vs $-0.35miss
- Mon, May 5$-0.50 vs $-0.44miss
Estimates and results for RXRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RXRX officers and directors.
- Bought
- —
- Sold
- $5.6m
0 trades
28 trades
- Khan Najatsold
- Borgeson Blakesold
- Borgeson Blakesold
- Borgeson Blakesold
- Bumpus Namandjesold
- Gibson Christophersold
- Khan Najatsold
- Bumpus Namandjesold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RXRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.